Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05864014
PHASE3

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.

Official title: Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

213

Start Date

2023-04-25

Completion Date

2025-09

Last Updated

2025-04-16

Healthy Volunteers

No

Interventions

DRUG

Hetrombopag

Hetrombopag

DRUG

Hetrombopag plus Placebo

Hetrombopag plus Placebo

DRUG

Placebo

Placebo

Locations (1)

Hematology Tumor Research Center of Harbin First Hospital

Haerbin, Heilongjiang, China